BCLI - Brainstorm Cell Therapeutics Inc.
| Previous Close | 4.0200 |
| Open | 3.9800 |
| Bid | 3.5000 x 1400 |
| Ask | 0.0000 x 800 |
| Day's Range | 3.9700 - 4.0500 |
| 52 Week Range | 2.9200 - 4.5000 |
| Volume | 45,199 |
| Avg. Volume | 131,878 |
| Market Cap | 90.427M |
| Beta (3Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8800 |
| Earnings Date | Oct 28, 2019 - Nov 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.50 |
- Simply Wall St.
Is Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Growing Too Fast?
Trailing twelve-month data shows us that Brainstorm Cell Therapeutics Inc.'s (NASDAQ:BCLI) earnings loss has...
- GlobeNewswire
BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer
Dr. Shah is an experienced healthcare finance professional with over 18 years of diverse leadership experience in investment banking and venture capital, healthcare financial consulting, business development, sales and marketing, and scientific research. Prior to his appointment as BrainStorm’s CFO, Dr. Shah served as Director of Healthcare Investment Banking at Barclays Capital Plc., where he focused on Life Sciences and Medical Device sectors, and was actively involved in closing more than $3.5 billion in M&A and equity transactions, and over $20bn in debt financings for publicly traded companies. Prior to his role at Barclays, Dr. Shah served as Vice President of Healthcare Investment Banking at Canaccord Genuity Inc., from July 2013 to May 2016, where he played an integral role in executing ~$1.5 billion in M&A transactions and equity financings for small and mid-cap publicly traded companies in the Medical Device and Diagnostics sectors.
- GlobeNewswire
BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress
NEW YORK, Sept. 06, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating.
- Zacks Small Cap Research
BCLI: 170 Patients Enrolled in Phase 3 ALS Trial…
BrainStorm Cell Therapeutics, Inc. (BCLI) is continuing to enroll patients in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of ALS. Cells will be extracted from each patient one time prior to treatment, with all administrations of NurOwn® derived from the same extraction of cells thanks to a cryopreservation process developed for long-term storage of mesenchymal stem cells (MSC). The company is focusing the trial on faster-progressing ALS patients since these patients demonstrated superior outcomes in the Phase 2 trial of NurOwn®.
- GlobeNewswire
BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update
Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: Special High-level FDA Meeting, Continued Progress in NurOwn® ALS Phase 3 Trialand.
- ACCESSWIRE
Brainstorm Cell Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, ...
- GlobeNewswire
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update
NEW YORK, Aug. 05, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- Simply Wall St.
If You Had Bought Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Three Years Ago, You Could Pocket A 59% Gain Today
One simple way to benefit from the stock market is to buy an index fund. But many of us dare to dream of bigger...
- GlobeNewswire
Third Clinical Site Initiated for BrainStorm Cell Therapeutic’s Phase 2 Progressive MS Study
NEW YORK, July 02, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- GlobeNewswire
BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting
NEW YORK and SEATTLE, May 31, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- GlobeNewswire
BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study
NEW YORK, May 30, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- GlobeNewswire
BrainStorm Senior Management to Present at BIO 2019
- Chaim Lebovits, President & CEO Corporate Presentation, June 4, 2019 - - Ralph Kern MD, MHSc, Chief Medical Officer & Chief Operating Officer Round Table Panelist,.
- Zacks Small Cap Research
BCLI: Enrollment in Phase 3 ALS Trial to Complete in 3Q19…
During the 71st American Academy of Neurology (AAN), BrainStorm Cell Therapeutics, Inc. (BCLI) presented two scientific abstracts that provided a detailed molecular characterization of neurotrophic factor production by NurOwn® and a correlation between cerebrospinal fluid biomarkers and clinical improvement in the Phase 2 ALS study. The following radar plot shows the fold change in the secretion of various neurotrophic factors (NTFs) by MSC-NTF compared to MSC, which varied from 2x to 9x for the tested NTFs.
- GlobeNewswire
BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and LONDON, May 13, 2019 -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases,.
- GlobeNewswire
BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update
Highlights Scientific Advances and Continued Progress in NurOwn® ALS Phase 3 Trial and Progressive MS Phase 2 Trial; Expansion of the proprietary cellular technology.
- GlobeNewswire
BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases
NEW YORK, April 30, 2019 -- Brainstorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today.
- Zacks Small Cap Research
BCLI: Two Abstracts to be Presented at AAN Annual Meeting…
On March 28, 2019, BrainStorm Cell Therapeutics, Inc. (BCLI) announced that two abstracts have been selected for presentation at the 71st American Academy of Neurology (AAN) Annual Meeting, which is being held May 4-10, 2019. The presentations focus on biomarker correlations with clinical outcomes in the phase 2 study and the genetic characterization of neurotrophic factor production in NurOwn®, one of which was selected for oral presentation during the ‘Emerging Science Session’. On March 13, 2019, BrainStorm Cell Therapeutics, Inc. (BCLI) held a conference call to announce that the Israeli Ministry of Health has approved the company’s application for the Hospital Exemption (HE) program, which will allow for the treatment of 13 amyotrophic lateral sclerosis (ALS) patients with NurOwn®.
- GlobeNewswire
Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
NEW YORK, March 28, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- GlobeNewswire
BrainStorm Announces Grant of an additional New European Patent for NurOwn®
NEW YORK, March 26, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today.
- GlobeNewswire
Atlas Blockchain Announces Definitive Agreement for the Acquisition of Isracann and Amendment to Investor Services Agreement
Atlas Blockchain Group Inc. (CSE:AKE) (A49.F) (ATLEF) (the “Company” or “Atlas”) is pleased to announce, further to its news release on October 11, 2018, the Company has entered into a definitive share exchange agreement dated March 12, 2019 (the “Share Exchange Agreement”), pursuant to which the Company has agreed to acquire all of the issued and outstanding common shares (the “Isracann Shares”) in the capital of Isracann Biosciences Inc. (“Isracann”), a private British Columbia company, from the shareholders of Isracann (the “Isracann Shareholders”), subject to the conditions set out in the Share Exchange Agreement (the “Transaction”).
- Zacks Small Cap Research
BCLI: Hospital Exemption Approved in Israel; First Patient Enrolled in Phase 2 Study in Progressive MS…
On March 13, 2019, BrainStorm Cell Therapeutics, Inc. (BCLI) held a conference call to announce that the Israeli Ministry of Health has approved the company’s application for the Hospital Exemption (HE) program, which will allow for the treatment of 13 amyotrophic lateral sclerosis (ALS) patients with NurOwn®. The patients to be treated were selected based on separate inclusion/exclusion criteria than is being used for the ongoing Phase 3 trial of NurOwn® in ALS. BrainStorm is continuing to enroll patients in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of ALS.
- GlobeNewswire
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
NEW YORK and CLEVELAND, March 14, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly.
- Simply Wall St.
Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc.'s (NASDAQ:BCLI): Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to addressRead More...
- Benzinga
The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 11) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
- GlobeNewswire
BrainStorm to Host Business Update Conference Call
NEW YORK, March 07, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
